Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 4D Pharma Begins Phase II COVID-19 Study | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

4D Pharma Begins Phase II COVID-19 Study

MRx-4DP0004, an immunomodulatory therapy, has shown potential to down-regulate hyper-inflammatory response while maintaining anti-viral response

By: Contract Pharma

Contract Pharma Staff

4D pharma plc, a pharmaceutical company developing Live Biotherapeutics, received expedited acceptance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to begin a Phase II study of MRx-4DP0004 in COVID-19 patients.

Current evidence suggests a reason for the high mortality rate of COVID-19 may be due to the hyper-inflammatory response and cytokine storm syndrome caused by uncontrolled activation of the immune system. Targeted immunomodulation may be beneficial in these patients.  

4D pharma’s Live Biotherapeutic MRx-4DP0004 is the first immunomodulatory therapy being tested in patients hospitalized with COVID-19 which has shown the potential to simultaneously down-regulate specific pathological aspects of the hyper-inflammatory response while maintaining the appropriate anti-viral response. As MRx-4DP0004 is not broadly immunosuppressive, it does not carry the inherent side-effects associated with immunosuppressants currently under investigation, such as increased risk of infections or cancer, that may preclude their use earlier in more mild-to-moderate patients, which is crucial to reducing the burden on health systems.

MRx-4DP0004 is an orally administered, single-strain Live Biotherapeutic product (LBP) currently in a Phase I/II clinical trial for the treatment of patients with partly-controlled asthma. 4D pharma has previously shown that MRx-4DP0004 is able to significantly reduce lung inflammation and impact particular immune cell types and pathways implicated in the hyperinflammatory response to SARS-CoV-2 infection.

The COVID-19 Phase II study of MRx-4DP0004 will be a randomized, double-blind, placebo-controlled trial that will evaluate efficacy and safety in addition to standard-of-care in up to 90 patients. The primary endpoint of the trial will be the mean change in clinical status. Secondary endpoints include safety and tolerability as well as a suite of additional measures of clinical efficacy including the need for and duration of ventilation.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters